Signal Says Which Biotech to Buy This Week Emma Duncan May 11, 2026 1 min read TGTX TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1.2% at $42.35, after last week being rejected by the overhead $44 ceiling. TGTX remains up 44% in 2026, however, recently breaking out above an channel ascending from the pharma giant's mid-March lows. More gains could be in order, too, per a historically bullish signal now flashing.
TGTX's outperformance comes amid historically low implied volatility (IV). Specifically, the equity's current SVI of 46% stands in the low 6th percentile of its annual range. According to data from Schaeffer's Senior Quantitative Analyst Rocky White, there have been four instances in the past five years when the equity traded within 2% of its 52-week high, while its Schaeffer's Volatility Index (SVI) ranked in the 20th percentile of its annual range or lower.
TGTX was higher one month later 75% of the time after those signals, averaging a 6.6% gain. From its current perch, a shift of this amount would put TGTX back above $45 -- a fresh annual high. tgtxintraday There is plenty of room for bulls to move in, with three of the nine analysts in coverage sporting a "hold" or worse rating. Shorts are firmly in control, too, with 19.4% of the stock's available float now sold short.
At the stock's average pace of trading it would take shorts over three weeks to buy back these bearish bets. {"contentId":"e5b29a88-9ec4-3376-93f9-9b19eaad2272","canonicalUrl":"https://finance.yahoo.com/markets/stocks/articles/historic-signal-says-biotech-outperforms-180025188.html","owningPropertyUrl":"https://finance.yahoo.com/markets/stocks/articles/historic-signal-says-biotech-outperforms-180025188.html","providerId":"schaeffers_investment_research_24","commerceSiteId":"","site":"finance","region":"US","lang":"en-US","tags":[,,,,,,,,,,,,,],"categories":[,,],"commerceArticleType":""} Terms and Privacy Policy EU DSA contact Privacy & Cookie Settings More Info
Extract — continue reading at the source.
